Physician profile
Maya Ingram
NPI 1518221464
$493.03
in general payments reported to CMS, 2019-2025
13 companies · $214 in 2025
The $214 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.85 · 2020: $29.79 · 2021: $43.57 · 2022: $29.33 · 2023: $64.57 · 2024: $56.55 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124.55 | 2025 | Penmenvy |
| Ironshore Pharmaceuticals INC. | $57.95 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $56.68 | 2021-2023 | Qelbree |
| Pfizer INC. | $55.86 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $40.12 | 2025 | Jornay Pm |
| Alkermes, INC. | $35.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.92 | 2022-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Ultragenyx Pharmaceutical INC. | $23.20 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $15.14 | 2024 | Flumist Quadrivalent |
| Novo Nordisk INC | $14.33 | 2020 | |
| Abbvie INC. | $14.30 | 2025 | |
| Corium, LLC | $14.14 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.